Via Pharmaceuticals (VIAP)

Via Pharmaceuticals, Inc. is a development-stage biotechnology company listed on OTC Markets under the symbol VIAP. The company focuses on discovering and developing small-molecule compounds for cardiovascular and metabolic diseases, with research aimed at conditions such as vascular inflammation, high cholesterol, high triglycerides, insulin sensitization, and diabetes. Its pipeline includes VIA-3196, a liver-directed thyroid hormone receptor beta agonist that is Phase 1 ready and intended to address dyslipidemia, including elevated LDL cholesterol, triglycerides, and Lp(a). The company is also developing a DGAT1 inhibitor in preclinical work for type 2 diabetes and related metabolic disorders, and VIA-2291, a 5-lipoxygenase inhibitor that has completed a third Phase 2 clinical trial for atherosclerotic plaque. Via Pharmaceuticals also has research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. The company was founded in 2004 and is headquartered in San Francisco, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.